Skip to main
MTVA

MTVA Stock Forecast & Price Target

MTVA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MetaVia is expected to deliver data in 4Q26 on their DA-1726 program, with focus on successful titration and increased weight loss. Additionally, looking for continued progress on vanoglipel and potential FDA guidance on their MASH program will be key. With $13.7M in cash and runway into 4Q26, their financials appear stable, but execution will remain a crucial factor in their success.

Bears say

MetaVia is facing significant questions regarding the outcome of their 4Q26 topline Phase 1 data readout for their novel GPR119 agonist, Vanoglipel. The success of the 64 mg dose in producing a meaningful dose-response benefit over 48 mg, along with tolerability profiles and potential differentiation in the increasingly crowded obesity/MASH market, will likely be the key determining factors for investors considering the efficacy of this drug. Ahead of the data readout, comparing the data against other drugs in the market and gathering insights from KOLs will be crucial in assessing the potential for differentiation and the overall success of the drug.

MTVA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroBo Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroBo Pharmaceuticals Inc (MTVA) Forecast

Analysts have given MTVA a Strong Buy based on their latest research and market trends.

According to 1 analysts, MTVA has a Strong Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroBo Pharmaceuticals Inc (MTVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.